Literature DB >> 29732989

Towards Breast Cancer Vaccines, Progress and Challenges.

Javad Behravan1,2,3, Atefeh Razazan1, Ghazal Behravan4.   

Abstract

Breast cancer is the second leading cause of cancer death among women. National cancer institute of the US estimates that one in eight women will be diagnosed with breast cancer during their lifetime. Considering the devastating effects of the disease and the alarming numbers many scientists and research groups have devoted their research to fight breast cancer. Several recommendations are to be considered as preventing measures which include living a healthy lifestyle, regular physical activity, weight control and smoking cessation. Early detection of the disease by annual and regular mammography after the age of 40 is recommended by many healthcare institutions. This would help the diagnosis of the disease at an earlier stage and the start of the treatment before it is spread to other parts of the body. Current therapy for breast cancer includes surgical ablation, radiotherapy and chemotherapy which is often associated with adverse effects and even may lead to a relapse of the disease at a later stage. In order to achieve a long-lasting anticancer response with minimal adverse effects, development of breast cancer vaccines is under investigation by many laboratories. The immune system can be stimulated by a vaccine against breast cancer. This approach has attracted a great enthusiasm in recent years. No breast cancer vaccines have been approved for clinical use today. One breast cancer vaccine (NeuVax) has now completed clinical trial phase III and a few preventive and therapeutic breast cancer vaccines are at different steps of development. We think that with the recent advancements in immunotherapy, a breast cancer vaccine is not far from reach. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Breast cancer; NeuVax; antigenic peptides; genetics; immunotherapy; pathology; vaccines.

Year:  2019        PMID: 29732989     DOI: 10.2174/1570163815666180502164652

Source DB:  PubMed          Journal:  Curr Drug Discov Technol        ISSN: 1570-1638


  7 in total

1.  Comparative proteomics study of proteins involved in induction of higher rates of cell death in mitoxantrone-resistant breast cancer cells MCF-7/MX exposed to TNF-α.

Authors:  Saeed Norouzi; Rezvan Yazdian Robati; Morteza Ghandadi; Khalil Abnous; Javad Behravan; Fatemeh Mosaffa
Journal:  Iran J Basic Med Sci       Date:  2020-05       Impact factor: 2.699

Review 2.  Trial watch: Peptide-based vaccines in anticancer therapy.

Authors:  Lucillia Bezu; Oliver Kepp; Giulia Cerrato; Jonathan Pol; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-09-06       Impact factor: 8.110

Review 3.  HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development.

Authors:  Atefeh Arab; Rezvan Yazdian-Robati; Javad Behravan
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2020-01-09       Impact factor: 4.291

4.  Stimuli-Responsive Biomaterials for Vaccines and Immunotherapeutic Applications.

Authors:  Noah Pacifici; Amir Bolandparvaz; Jamal S Lewis
Journal:  Adv Ther (Weinh)       Date:  2020-08-02

5.  Role of ADCC, CDC, and CDCC in Vaccine-Mediated Protection against Her2 Mammary Carcinogenesis.

Authors:  Marco Macagno; Silvio Bandini; Elisabetta Bolli; Amanda Bello; Federica Riccardo; Giuseppina Barutello; Irene Fiore Merighi; Guido Forni; Alessia Lamolinara; Francesco Del Pizzo; Manuela Iezzi; Federica Cavallo; Laura Conti; Elena Quaglino
Journal:  Biomedicines       Date:  2022-01-21

Review 6.  New and Emerging Targeted Therapies for Advanced Breast Cancer.

Authors:  Kristie H Lau; Alexandra M Tan; Yihui Shi
Journal:  Int J Mol Sci       Date:  2022-02-18       Impact factor: 5.923

Review 7.  Recent Progress on Immunotherapy for Breast Cancer: Tumor Microenvironment, Nanotechnology and More.

Authors:  Yang Li; Wenfang Miao; Doudou He; Siqi Wang; Jianjuan Lou; Yanni Jiang; Shouju Wang
Journal:  Front Bioeng Biotechnol       Date:  2021-06-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.